Clinical trials
Kidney Transplant Infection clinical trials
Below are recruiting kidney transplant infection clinical trials, each written for real people, not researchers. We’re tracking 113 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07508787RecruitingPhase 2
Study comparing siplizumab to another drug for kidney transplant acceptance
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Sacramento, CaliforniaAges 18–70 - NCT03591302RecruitingPhase 1
Stem cell transplant to stop anti-rejection drugs after kidney transplant
This study tries to use a stem cell transplant from your original kidney donor to help your body accept the kidney without needing lifelong anti-rejection drugs. You must have a perfectly matched sibling donor who is still available.
Palo Alto, CaliforniaAges 18 years+ - NCT06801886Enrolling by invitationPhase 3
Silymarin for better kidney transplant success
This trial tests if adding silymarin (a milk thistle extract) to standard anti-rejection medicines helps protect the new kidney from damage. It may improve how well the transplanted kidney works over time.
MartinAges Any age - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Birmingham, AlabamaAges 13–20 - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT06095492Recruiting
Comparing diabetes drugs after kidney transplant
This trial tests two diabetes medications, empagliflozin and linagliptin, to see which one works better for controlling blood sugar, protecting kidney function, and improving body composition in people who have had a kidney transplant and have diabetes.
Gurgaon, HaryanaAges 30 years+ - NCT07090512Recruiting
Ultrasound to predict kidney risk after transplant
This study uses ultrasound of donor kidneys to predict the risk of kidney problems after transplant. It may help doctors better understand transplant outcomes.
Jinan, ShandongAges 18 years+ - NCT07539857RecruitingPhase 2
Belimumab to help highly sensitized kidney transplant candidates
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
LeidenAges 18 years+ - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT06625073RecruitingPhase 4
SGLT2i for heart transplant recipients
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
Palo Alto, CaliforniaAges 18 years+ - NCT04989491RecruitingPhase 4
Single-dose rituximab to prevent EBV after kidney transplant
This trial tests whether one dose of rituximab (given around the time of transplant) can help prevent a first Epstein-Barr virus (EBV) infection and related abnormal lymph node or immune growths after kidney transplant. It is specifically for adults who are EBV-negative before receiving an EBV-positive donor kidney.
StrasbourgAges 18 years+ - NCT07393594Enrolling by invitation
Tracer study for kidney transplant monitoring
This study looks at a new blood test to help monitor the health of your transplanted kidney and check for early signs of rejection. The test will be done as part of your usual care after a kidney transplant.
Phoenix, ArizonaAges 18 years+ - NCT07009548Enrolling by invitationPhase 4
CytoGam for CMV in solid organ transplant recipients
This trial tests whether adding CytoGam (an antibody treatment) to standard antiviral therapy can better treat CMV (a common virus) in people who have received a solid organ transplant. It may help those with high virus levels or a new infection after transplant.
Pittsburgh, PennsylvaniaAges 18–75 - NCT05385432RecruitingPhase 3
Kidney transplant induction therapy for sensitized patients
This trial tests a specific “induction” treatment to help people who have stronger immune reactions from past sensitizing events during a kidney transplant. It may help improve how well the transplant works and how safely the immune system is managed.
ToursAges 18–79 - NCT06568549RecruitingPhase 4
Reducing Immunosuppression in Older Kidney Transplant Patients (RIOT Trial)
This trial tests whether older kidney transplant recipients can safely reduce their immunosuppression medications using a special monitoring tool called Trugraf. If you are over 55, have had a stable transplant, and want to possibly lower your medications, this study may be for you.
Phoenix, ArizonaAges 55 years+ - NCT07347769Recruiting
BK virus risk study in kidney transplant patients
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
GrenobleAges 18 years+ - NCT06263426Recruiting
Kidney transplant from donors with HIV: impact on rejection and long-term results
This study tests whether kidney transplants from donors with HIV are safe and effective for people with HIV who need a new kidney. It looks at long-term outcomes like rejection and survival.
Birmingham, AlabamaAges 18 years+ - NCT05159466Recruiting
Transplant from HIV-positive donors to HIV-positive recipients
This trial studies whether it’s safe and effective for HIV-positive people to receive organ transplants from HIV-positive donors. It focuses on matching HIV treatment before and after transplant and checking for major complications.
Metairie, LouisianaAges 18 years+ - NCT07426484RecruitingPhase 4
Testing cosibelimab for advanced skin cancer in specific patients
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Boston, MassachusettsAges 18 years+ - NCT07333495Recruiting
Using MRI to check kidney transplant health
This study tests if a special MRI (without dye) can accurately measure how well a transplanted kidney is working. It is for people who have received a kidney transplant or a combined kidney-pancreas transplant, and for living donors.
Shiyan, HubeiAges 18 years+ - NCT07199465RecruitingPhase 1
Letermovir for children after a kidney transplant
This study tests an oral antiviral medication called letermovir to see if it safely prevents CMV (a common virus) in children who have recently had a kidney transplant. It's for children ages typically 4 weeks to about a year post-transplant, with stable kidney function and no current CMV infection.
Birmingham, AlabamaAges Up to 17 years - NCT07024238Enrolling by invitation
Short-chain fatty acid supplement for kidney transplant patients
This study tests whether taking a short-chain fatty acid (a type of fiber-like substance) supplement can improve gut health in people who have had a kidney transplant. It may help keep the transplant working well.
Martin, SlovakiaAges 18 years+
Hear when a new Kidney Transplant Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for kidney transplant infection?
- Yes. Clin2 currently lists 113 recruiting kidney transplant infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a kidney transplant infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a kidney transplant infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.